Shares of drugmaker Teva (NYSE:TEVA) stumbled in 2013, finishing the year far behind the S&P 500.
Today, however, this stock trades at an attractive multiple and could be set for a rebound in 2014. But is it smooth sailing ahead for this unique drugmaker, or are there challenges in the coming years that should worry investors? Analyst Max Macaluso explores this stock in the following video and presents one reason to avoid Teva and one reason to be optimistic about the stock's future.
Editor's Note: At 2:37, Max meant to say Teva appointed "Erez Vigodman."